Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107051 | 0.88 | CYP2A13 (1.00) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4105461 | 0.84 | CYP2A13 (1.00) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20256954 | 0.82 | CYP2A13 (0.69) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20256851 | 0.82 | CYP2A13 (0.69) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL30596550 | 0.80 | KDM4E (0.70) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3311657 | 0.79 | CYP2A13 (1.00) | CYP2A13KDM4EALDH1A1CXCR4RAB9A | |
| SCHEMBL18190383 | 0.78 | CYP2A13 (0.71) | CYP2A13KDM4EALDH1A1CXCR4HRH3 | |
| SCHEMBL15093763 | 0.77 | CYP2A13 (0.61) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4109734 | 0.77 | CYP2A13 (0.62) | CYP2A13KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3966949 | 0.77 | CYP2A13 (0.62) | CYP2A13KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | claimed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | claimed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885KDM4E 2221/4885ALDH1A1 120/4885 |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885KDM4E 2221/4885ALDH1A1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.